CN1115152C - 用尿苷三磷酸及相关化合物治疗支气管炎的方法 - Google Patents

用尿苷三磷酸及相关化合物治疗支气管炎的方法 Download PDF

Info

Publication number
CN1115152C
CN1115152C CN97199444A CN97199444A CN1115152C CN 1115152 C CN1115152 C CN 1115152C CN 97199444 A CN97199444 A CN 97199444A CN 97199444 A CN97199444 A CN 97199444A CN 1115152 C CN1115152 C CN 1115152C
Authority
CN
China
Prior art keywords
compound
bronchi
utp
bronchioles
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97199444A
Other languages
English (en)
Chinese (zh)
Other versions
CN1236318A (zh
Inventor
C·L·谢弗
R·C·鲍彻
J·L·赖德奥特
K·M·雅格布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Merck Sharp and Dohme LLC
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of CN1236318A publication Critical patent/CN1236318A/zh
Application granted granted Critical
Publication of CN1115152C publication Critical patent/CN1115152C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN97199444A 1996-11-07 1997-10-21 用尿苷三磷酸及相关化合物治疗支气管炎的方法 Expired - Lifetime CN1115152C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/744,367 1996-11-07
US08/744,367 US6159952A (en) 1996-11-07 1996-11-07 Method of treating bronchitis with uridine triphosphate and related compounds

Publications (2)

Publication Number Publication Date
CN1236318A CN1236318A (zh) 1999-11-24
CN1115152C true CN1115152C (zh) 2003-07-23

Family

ID=24992452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97199444A Expired - Lifetime CN1115152C (zh) 1996-11-07 1997-10-21 用尿苷三磷酸及相关化合物治疗支气管炎的方法

Country Status (14)

Country Link
US (1) US6159952A (enExample)
EP (1) EP0941099B1 (enExample)
JP (1) JP2001505553A (enExample)
KR (1) KR100518066B1 (enExample)
CN (1) CN1115152C (enExample)
AT (1) ATE249833T1 (enExample)
AU (1) AU744981B2 (enExample)
BR (1) BR9714312A (enExample)
CA (1) CA2271126C (enExample)
DE (1) DE69724991T2 (enExample)
ES (1) ES2207723T3 (enExample)
NO (1) NO992197L (enExample)
NZ (1) NZ335540A (enExample)
WO (1) WO1998019685A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
EP1012154B1 (en) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6251693B1 (en) 1998-07-30 2001-06-26 Micron Technology, Inc. Semiconductor processing methods and semiconductor defect detection methods
AR023088A1 (es) * 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
GB2394419B (en) 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
EP1750740A4 (en) * 2004-05-06 2009-06-10 Molichem Medicines Inc TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US3960840A (en) * 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
DK0508687T3 (da) * 1991-04-06 1996-02-05 Astra Pharma Prod ATP-analoger
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
DE69724991D1 (de) 2003-10-23
ATE249833T1 (de) 2003-10-15
CA2271126A1 (en) 1998-05-14
BR9714312A (pt) 2000-05-02
AU744981B2 (en) 2002-03-07
JP2001505553A (ja) 2001-04-24
CA2271126C (en) 2008-04-08
KR100518066B1 (ko) 2005-09-28
DE69724991T2 (de) 2004-11-11
CN1236318A (zh) 1999-11-24
US6159952A (en) 2000-12-12
ES2207723T3 (es) 2004-06-01
EP0941099A1 (en) 1999-09-15
NZ335540A (en) 2001-05-25
AU4986697A (en) 1998-05-29
WO1998019685A1 (en) 1998-05-14
KR20000053094A (ko) 2000-08-25
EP0941099B1 (en) 2003-09-17
NO992197L (no) 1999-07-05
NO992197D0 (no) 1999-05-05

Similar Documents

Publication Publication Date Title
CN1115152C (zh) 用尿苷三磷酸及相关化合物治疗支气管炎的方法
CN1229114C (zh) 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
EP0938322B1 (en) Use of uridine triphosphate related compounds for the prevention and treatment of pneumonia in immobilized patients
CN1086940C (zh) 用于治疗肺病的二核苷酸
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
JP2001513568A (ja) 肺疾患を治療するためのウリジン５’−ジホスフェートとその類似体の使用
JP2002532520A (ja) 気道病治療および気道用薬剤送達のための化合物および方法
CN1284861A (zh) 尿苷三磷酸的新型药物组合物
CA2354576C (en) Pharmaceutical preparation for inhalation of an opioid
JP2009500354A (ja) 肺疾患を治療するためのｐ２ｙ６受容体アゴニスト
KR20140001877A (ko) 흡입 데누포솔에 의한 낭포성 섬유증의 치료 방법
WO1999001138A1 (en) A pharmaceutical formulation of uridine triphosphate suitable for administration in a small volume
HK1022263A (en) Method of treating bronchitis with uridine triphosphates and related compounds
US20130123364A1 (en) N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs
MXPA99004283A (en) Method of treating bronchitis with uridine triphosphates and related compounds
US20090098209A1 (en) Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
Pavia et al. Lung mucociliary transport in man
EP4304552A1 (en) Novel antiviral compositions and their use in therapy and in the treatment of viral infections
WO2022065860A1 (ko) 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
HK1034464A (en) Novel pharmaceutical compositions of uridine triphosphate
CN101237772A (zh) 用于治疗肺病的p2y6受体激动剂
HK1021136A (en) Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients
HK1017843A (en) Dinucleotides useful for the treatment of lung disease
JPS62223123A (ja) 去痰剤
HK1022099A (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NORTH CAROLINA UNIVERSITY CHAPEL HILL CAMPUS

Free format text: FORMER OWNER: INSPIRE PHARMACEUTICALS, INC.

Effective date: 20040329

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20040329

Address after: North Carolina

Patentee after: The University of North Carolina AT Chapel Hill

Address before: North Carolina

Patentee before: Inspire Pharmaceuticals, INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1022263

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: INSPIRE PHARMACEUTICALS, INC.

Free format text: FORMER OWNER: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Effective date: 20150420

Owner name: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Effective date: 20150420

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150420

Address after: North Carolina

Patentee after: Inspire Pharmaceuticals, INC.

Patentee after: The University of North Carolina AT Chapel Hill

Address before: North Carolina

Patentee before: The University of North Carolina AT Chapel Hill

ASS Succession or assignment of patent right

Owner name: MSD CORP.

Free format text: FORMER OWNER: INSPIRE PHARMACEUTICALS, INC.

Effective date: 20150727

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150727

Address after: new jersey

Patentee after: Schering Corporation

Patentee after: The University of North Carolina AT Chapel Hill

Address before: North Carolina

Patentee before: Inspire Pharmaceuticals, INC.

Patentee before: The University of North Carolina AT Chapel Hill

CX01 Expiry of patent term

Granted publication date: 20030723

CX01 Expiry of patent term